Crispr Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Oppenheimer decreased their Q1 2020 earnings per share (EPS) estimates for shares of Crispr Therapeutics in a note issued to investors on Monday, November 25th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their prior estimate of ($0.87). Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
CRSP has been the subject of several other reports. BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Finally, TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $69.54.
Shares of CRSP opened at $65.36 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company’s 50 day simple moving average is $58.93 and its 200-day simple moving average is $48.44. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. raised its stake in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth $21,167,000. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Do back-end load funds outperform no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.